PERSPECTA

News from every angle

← Back to headlines

Phathom Pharmaceuticals Shifts Focus to GI, Aims for Profitability by 2026

Phathom Pharmaceuticals announced a strategic pivot towards gastrointestinal focus and targets profitability by the second half of 2026, as revealed by its CEO at the Guggenheim Summit.

PostShare

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

YahooCatalan192d ago

Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit

Read full article →

Related Stories

U.S. Economy Expands at Sluggish 1.5% Pace in Second Quarter

38m ago

Gold Prices Surge to Record $4,600 Per Ounce

1h ago

J.M. Smucker Raises Full-Year Forecast After Strong Q1 Results

2h ago

July PCE Inflation Rises Slightly, Driven by Financial Services

2h ago